Aurigene's AUR101 disappoints in Phase IIb study in moderate to severe psoriasis

Indian biotech Aurigene Oncology on Friday day reported results of INDUS-3, a Phase IIb double blind placebo-controlled study of AUR101 conducted in the USA, in patients with moderate to severe psoriasis, which, though hitting its main goal, failed to meet expectations.

Aurigene is a wholly owned subsidiary of Indian pharma major Dr Reddy’s Laboratories (BSE: 500124), whose shares closed down 2.1% at 4,375 rupees following the announcement.

The INDUS-3 study, listed at clinicaltrials.gov with identifier NCT04855721, met its primary endpoint of PASI-75 response at 12 weeks at the 400mg BID dose, when compared to placebo. The primary endpoint of PASI-75 at 12 weeks at the 200mg BID dose and the 400mg QD dose were not met. There were no safety issues identified in the study. Hiwever, Aurigene will be closing the clinical development of AUR101 in psoriasis.